Background Pharmacotherapy combinations have been shown to improve survival and reduce hospitalisations in adults with ...
Modeling at 2023 net pricing estimated semaglutide would avert >358,000 cardiovascular events/deaths, saving ~$15B in cardiovascular care plus ~$8B in other care, but adding ~$344B lifetime drug spend ...
A new study claims a certified registered nurse anesthetist working as the sole anesthesia provider is the most cost-effective model of anesthesia delivery and doesn’t impact care quality, according ...
Emilie Aschenbrenner, PharmD, BCOP, outlines how Froedtert Health and the Medical College of Wisconsin use outpatient-based care models, standardized protocols, and collaborative partnerships to ...
The company says the new "Qwen2.5-Omni-7B" is a multimodal model that can process text, images, audio, and videos, while generating real-time text and natural speech responses. Amid China's AI fervor ...
Treatment with abelacimab could result in potential cost-savings of $50,000 over a lifetime per patient basis and higher quality-adjusted life years in atrial fibrillation patients at a high risk of ...
A hypothetical cohort of women, assumed to be initially free of osteoporosis-related bone fractures, is followed on an annual basis for 25 years. Women in the cohort face risks for three important ...
For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows. However, ...
Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is partly ...
Background. Clostridium difficile infection (CDI) is the most commonly recognized cause of recurrent diarrhea. Bezlotoxumab, administered concurrently with antibiotics directed against C. difficile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results